Melanie M Tidman

Dr. Melanie M Tidman

College of Graduate Health Studies, A.T. Still University, Mesa, Arizona, USA
+3
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Neurodegenerative Disease Management
Verified
Journal Article
Open access
MTMelanie M Tidman
Melanie M Tidman
DWDawn Reid White
Dawn Reid White
TWTimothy White
Timothy White
Aim: To evaluate a low carbohydrate/healthy fat/ketogenic diet (LCHF/KD) on symptoms, depression, anxiety and biomarkers in adults with Parkinson's disease (PD). Patients & methods: 16 adults ages ...

13 June 2024 in Neurodegenerative Disease Management
Verified
Journal Article
Open access
MTMelanie M Tidman
Melanie M Tidman
DWDawn Reid White
Dawn Reid White
Tim A WhiteTim A White
Tim A White
Aim: Evidence suggests low-carbohydrate diets (LCHF) may assist in treating neurodegenerative diseases such as Parkinson's disease (PD); however, gaps exist in the literature.Patients & methods: We conducted a small 24-week pilot study to investigate the effects of an LCHF diet on motor and nonmotor symptoms, health biomarkers, anxiety, and depression in seven people with PD. We also captured patient experiences during the process (quality of life [QoL]).Results: Participants reported improved biomarkers, enhanced cognition, mood, motor and nonmotor symptoms, and reduced pain and anxiety. Participants felt improvements enhanced their QoL.Conclusion: We conclude that an LCHF intervention is safe, feasible, and potentially effective in mitigating the symptoms of this disorder. However, more extensive randomized controlled studies are needed to create generalizable recommendations.

31 March 2022 in Cureus
Verified
Journal Article
Open access
MTMelanie M Tidman
Melanie M Tidman
The ketogenic diet has grown in popularity as an alternative or adjunct to medication therapy for Parkinson's disease (PD) and other neurodegenerative diseases (NDD). Traditional medication therapies often fail to produce desired improvements in PD symptoms and can have little or no effect on symptoms of depression and anxiety that often accompany a PD diagnosis. We document a case study involving a 68-year-old female with PD stage I and a history of mild symptoms of anxiety and depression. The subject adopted a traditional ketogenic diet (fats 70%; protein 25%; carbohydrates 5%) for 24 weeks. Baseline, 12-week and 24-week biomarkers (lab results), and scores on a depression scale, anxiety scale, and the Unified Parkinson's Disease Rating Scale (UPDRS) (parts I-III) for PD symptoms were compared. Significant improvements were observed in all health biomarkers, including a reduction in HbA1C, C-reactive protein (CRP), triglycerides, and fasting insulin, along with weight loss and reduction in cardiac risk factors. Improved high-density lipoprotein (HDL) levels were seen at 12 weeks and 24 weeks, along with improved anxiety symptoms at the 12-week and 24-week mark. Minimum improvement was seen on depression scale scores at 24 weeks. Based on our findings, the ketogenic diet is safe and effective for improving biomarkers of health, symptoms of depression, anxiety, and PD symptoms in patients with stage I PD. We recommend further clinical trial studies for more generalizable results.

7 February 2020 in Neurodegenerative Disease Management
Verified
Journal Article
Closed access
MTMelanie M Tidman
Melanie M Tidman
ESErin Skotzke
Erin Skotzke
Aim: The primary objective of the study was to evaluate the effects of a community-based exercise program for adults with Parkinson's disease (PD). Patients & methods: This one-group pretest and po...

21 December 2023 in Journal of Metabolic Health
Verified
Journal Article
Open access
PDF file
MTMelanie M Tidman
Melanie M Tidman
The use of therapeutic carbohydrate restriction (TCR) in the form of a ketogenic diet (KD) in neurodegenerative disorders such as Parkinson’s disease (PD) is increasing as an alternative treatment for primary and secondary symptoms. There exists a gap in the literature on symptoms of PD in the setting of metabolic syndrome (MetSyn) and possible comorbid impact on symptoms, biomarkers of health, cardiac risk, depression and anxiety. This case report documents a 24-week KD intervention for a 53-year-old man with multiple comorbid diagnoses, PD (Hoehn-Yahr stage IIa) with a history of morbid obesity with increased waist circumference, prediabetes, hyperinsulinaemia and significantly impaired mobility with chronic back pain, anxiety disorder and depression. Baseline cardiac risk ratios (CRR = triglycerides/HDL) were calculated and compared. The KD approach involved a well-formulated, ketogenic diet (fats 70%; protein 25%; carbohydrates 5% according to total daily energy intake for 24 weeks). Baseline, 12-week and 24-week biomarkers and scores on scales were compared. Clinically significant results were found when baseline biomarker results and scales were compared with 12-week results. Positive trends were seen for all variables at 24 weeks. Improvements in health biomarkers, including HbA1C, high sensitivity C-reactive protein (hs-CRP), triglycerides, fasting insulin, weight loss, waist circumference and cardiac risk were observed at 12 and 24 weeks. Some improvements in scores on an anxiety scale were seen. Based on our findings, KD is safe and effective for improving health biomarkers and symptoms of MetSyn, depression, anxiety and symptoms of PD. Future clinical trial studies for more generalisable results are needed.